Now showing items 1-10 of 10
Cladribine: Off-label disease modification for people with multiple sclerosis in resource-poor settings?
Background: A considerable number of people with multiple sclerosis (pwMS) live in low- and middle-income countries (LMIC), where lack of resource adversely affects access to effective disease-modifying treatment. Objective: ...
Treating the ineligible: Disease modification in people with multiple sclerosis beyond NHS England commissioning policies.
(Elsevier/Science Direct, 2018-11-02)
BACKGROUND: Whilst there is a broad selection of drugs licensed as disease modifying treatments (DMTs) for people with relapsing multiple sclerosis (pwRMS), access to DMTs remains restricted, particularly for people with ...
No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine.
OBJECTIVE: To compare the cancer risk of cladribine and other disease-modifying drugs (DMDs) in trials of people with relapsing multiple sclerosis (pwRMS). METHODS: Meta-analysis of phase III trials of licensed DMDs for ...
FLAIR* for the non-invasive histological diagnosis of MS
Objectives: To explore whether FLAIR* is superior to current MRI criteria for a diagnosis of MS using MRI datasets acquired at a single time point and a standard field strength (3T). Background: Current MRI criteria to ...